Intec Pharma Says Novartis Ends Development Agreement
December 11 2019 - 8:20AM
Dow Jones News
By Colin Kellaher
Intec Pharma Ltd. (NTEC) on Wednesday said Novartis AG (NOVN.EB,
NVS) has terminated an agreement for the development of a
custom-designed Accordion Pill for a proprietary compound.
The Jerusalem clinical-stage biopharmaceutical company said that
although the program met Novartis' technical and pharmacokinetic
clinical specifications, the Swiss drug maker decided that it no
longer meets its mid- to long-term strategic goals.
Intec said it will receive $1.5 million from Novartis on the
conclusion of the program.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
December 11, 2019 08:05 ET (13:05 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Novartis (NYSE:NVS)
Historical Stock Chart
From Sep 2023 to Sep 2024